AAPL 228.6 0.4261% MSFT 412.7838 0.7404% NVDA 134.1695 3.3345% GOOGL 186.805 0.7904% GOOG 188.574 0.7663% AMZN 232.82 1.6016% META 715.35 0.1162% AVGO 235.392 4.6791% LLY 864.92 -1.5245% TSLA 358.0225 -0.9948% TSM 207.7 0.7665% V 351.34 0.954% JPM 271.4399 -1.5809% UNH 527.98 0.1803% NVO 83.95 -2.8581% WMT 102.26 1.0974% LVMUY 141.59 0.6826% XOM 110.81 1.7632% LVMHF 707.0 0.6105% MA 566.5 0.6664%
AAPL 228.6 0.4261% MSFT 412.7838 0.7404% NVDA 134.1695 3.3345% GOOGL 186.805 0.7904% GOOG 188.574 0.7663% AMZN 232.82 1.6016% META 715.35 0.1162% AVGO 235.392 4.6791% LLY 864.92 -1.5245% TSLA 358.0225 -0.9948% TSM 207.7 0.7665% V 351.34 0.954% JPM 271.4399 -1.5809% UNH 527.98 0.1803% NVO 83.95 -2.8581% WMT 102.26 1.0974% LVMUY 141.59 0.6826% XOM 110.81 1.7632% LVMHF 707.0 0.6105% MA 566.5 0.6664%

Stocks under $1 Report

US and Canadian markets settled this week on a positive note, Two stocks to consider – GLO, UNCY

Jan 24, 2025

GLO:TSX
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (CA$)
UNCY:NASDAQ
Investment Type
Small-Cap
Risk Level
Action
Rec. Price (US$)

Company Overview: Global Atomic Corp. (TSX: GLO) is an interesting player in the resource sector, with its dual focus on high-grade uranium mine development and cash-flowing zinc concentrate production. Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company specializing in developing innovative therapies for kidney diseases and related medical conditions. The Report covers the Price Action, Technical Indicators Analysis along with the Stop Loss Levels, Target Prices, and Recommendations on these two stocks.

Global Markets Wrap-Up 

On January 23, 2025, the S&P 500 index settled at 6118.71 with a week till date gain of 1.15%; moreover, the tech-heavy NASDAQ composite advanced by ~2.16% on a WTD basis and settled at 20053.68. While the Russell 2000 settled at 2314.60, reflecting a gain of ~1.70% on a WTD basis.

Considering the Canadian market, the benchmark S&P/TSX Venture Composite Index (TSX: ^JX) started the week on a positive note and continued the momentum. On January 23, 2025, the index closed at 616.94 with an overall week-to-date (WTD) gain of 0.10%. Energy and healthcare were the leading sectors, while consumer non-cyclicals, real estate, consumer cyclicals, technology, basic materials and Industrials were the laggards on Thursday. 

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   


Disclaimer-

Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions  and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.